Atrial Fibrillation Market Forecast Worth USD 16.17 billion by 2020: Grand View Research, Inc.

The global atrial fibrillation market is expected to reach USD 16.17 billion by 2020. Rising occurrence of strokes, brain damage and atrial fibrillation owing to blood clots along with an increasing geriatric population is expected to drive industry growth. Technological advancements in the field of microwave catheter ablation and radiofrequency along with rising occurrence of diseases caused by lifestyle habits such as drinking and smoking are further expected to fuel growth. Moreover, increasing demand for smaller cardiac incisions, minimally invasive procedures and small recovery time post-surgery are projected to bolster growth. Also, global aging population combined with the changes in lifestyle increasing the risks of obesity and high blood pressure is likely to drive demand.
Pharmacological products accounted for over 50% market share in 2013. Low prices of these products along with increasing use of anti-coagulants as an add-on therapy to non-pharmacological procedures are expected to drive demand.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry

Further Key findings from the study suggest:

·         North America accounted for over 40% of global revenue in 2013. High penetration of non-pharmacological procedure and sophisticated reimbursement frameworks has resulted in its substantial demand over the past few years. High patient awareness and healthcare expenditure levels also contributed significantly towards region growth.

·         Asia-Pacific is expected to witness substantial growth during the forecast period, growing at a CAGR of over 13% from 2015 to 2022. Rising demand for non-pharmacological treatments due to improvement in healthcare infrastructure, high disposable incomes, and growing patient awareness are a few factors accounting for its rapid growth.

·         Radiofrequency catheter ablation procedure segment is expected to be the fastest growing segment with a CAGR of over 12% over the forecast period. Technological advancements related to maneuverability which helps in making tight bends inside the heart, the optimal size of the lesion produced and lower time required to recover from of catheter ablation is expected to drive demand over the next seven years.

·         Maze surgery occupied the second largest share of non-pharmacological treatment market. It removes the need for life-long anti-coagulants based treatment while reducing the occurrence of strokes. Anti-coagulants held the dominant market share in pharmacological treatment market as it reduced the incidence of blood clots and strokes which in turn is likely to propel demand over the projected period.

·         Key industry players include Boston Scientific Corporation, St. Jude Medical Inc., Johnson & Johnson Ltd., Sanofi-Aventis, CardioFocus Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Corporation, Biosense Webster Inc., AtriCure Inc. and Endoscopic Technologies Inc. St. Jude Medical Inc. developed an Endosense’sTactiCath. The technology provides live feedback related to pressure applied during microwave catheter ablations and radiofrequency.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/healthcare

Grand View Research has segmented the global atrial fibrillation market on the basis of fields of procedures and region:
Atrial Fibrillation Procedures Outlook
            • Pharmacological Products
                    • Anti-arrhythmic Drugs
                    • Anti-coagulant Drugs
            • Non-Pharmacological Treatment
                    • Catheter Ablation Procedures
                            • Radiofrequency
                            • HIFU
                            • Cryoablation
                            • Microwave
                            • Laser
                    • Maze Surgery
                    • Electric Cardioversion
Atrial Fibrillation Regional Outlook
            • North America
            • Europe
            • Asia Pacific
            • RoW

Bench-top Dental Autoclaves Market Is Expected To Reach USD 64.35 million By 2020, Growing At A CAGR Of 6.5% From 2014 To 2020

Global bench-top dental autoclaves market is expected to reach USD 64.35 million by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of dental disorder and rising patient awareness levels pertaining to sterilization are some major growth impacting drivers of this market. With remote and mobile healthcare access becoming the need of the hour, bench-top dental autoclaves are expected to witness a surge in demand over the next six years. In addition, growing number of initiatives aimed at curbing hospital acquired healthcare infections related expenditure via sterilization is expected to enhance market demand during the forecast period.
Automatic bench-top autoclaves are the most lucrative segment of this market and are expected to grow at a CAGR of over 6.5% during the forecast period. Growing demand for automatic bench-top dental autoclaves, on account of its ability to render error free and faster results is one of the major factors accounting for the segment’s rapid growth. Additionally, North American and European countries pursuing device automation, is expected to positively impact market growth over the next six years.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/bench-top-dental-autoclave-market

Further key findings from the study suggest:

• Pre and post vacuum bench-top autoclaves were the leading product segment in 2013. High market penetration rates and cost effectiveness associated with these products are some factors accounting for its large share.
• North America was the most revenue generating region, accounting for over 40.0% of the market in 2013. Major factors attributing to its large share include the presence of relatively higher healthcare expenditure and patient awareness levels and large dental procedure volumes. Extensive presence of government initiatives monitoring and implementing medical device sterilization in the region is also expected to drive market growth.
• Asia Pacific is expected to present this market with lucrative future growth opportunities. Large prevalence of dental diseases and rising patient awareness levels coupled with improving healthcare framework in the emerging markets of India and China are expected to result in a surge in product demand during the forecast period. Increasing number of dental procedures and a heightened need for safe medical practices owing to quickly rising demand for dental tourism in these markets are also expected improve device usage rates.
• Some key players of the bench-top dental autoclaves market include Tuttnauer, FONA Dental, W&H Dentalwerk International, Melag, Midmark  and Antonio Matachana.
• Development of technologically advanced and cost effective products via rigorous R&D investments is a key growth strategy adopted by these players. These companies also enter into strategic alliances with dentists and focus on enhancing brand awareness through community activities.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

For the purpose of this study, Grand View Research has segmented the global bench-top dental autoclaves market on the basis of product and region:
Global Bench-top Dental Autoclaves Product Outlook (Revenue, USD Million, 2012 – 2020)
    • Pre and Post Vacuum
    • Semi Automatic
    • Automatic
Bench-top Dental Autoclaves Regional Outlook (Revenue, USD Billion, 2012 – 2020)
    • North America
    • Europe
    • Asia Pacific
    • RoW

In-vitro Toxicology Testing Market Projected To Be Worth $44.7 Billion By 2022, Owing To Increased Demand In Various Pharmaceutical And Cosmetic Industries

The global in-vitro toxicology testing market is expected to reach USD 44.7 billion by 2022 growing at an estimated CAGR of 10.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected rise in demand can be ascribed to novel and promising technologies in analytical laboratories.
Advancement in bioinformatics based research for development of efficient software algorithms in order to carry out efficient stimulation of in-silico animal models in determination of toxicological response is expected to influence sector growth through to 2022.
Furthermore, rapid up gradation of databases that serve information for toxicity profiling and lethal dose determination of different compounds is anticipated to create significant potential for growth in this market during the forecast period.
Rise in government imposed restrictions and guidelines on usage of animals for pre-clinical research and toxicology testing is also attributive towards estimated progress in this industry.
Additionally, increasing R&D in biotechnology sector for enhancement in cell based assays and cell culture techniques, is anticipated to impart significant growth potential in this sector.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/in-vitro-toxicology-testing-market

Further key findings from the study suggest:

·         Pharmaceutical and cosmetic industry together accounted for almost 65% of total revenue generated in this sector for 2014. This large share can be attributed to rapid novel product launches for treatment of different diseased conditions wherein toxicological testing is the pre-requisite step. 

·         Cell culture technology contributed for over 42% of the revenue generated in the industry with respect to technology owing to critical role of cell culture in biotechnological development and cell based analysis 

·         Omics technology is anticipated to register lucrative growth thereby driving demand due to advancement in sequencing methods and availability of different platforms depending on source and target sequence. 

·         As a fundamental process in biopharmaceutical or pharmaceutical product development toxicological testing finds application in determination of systemic, dermal, & ocular toxicity as well as endocrine disruption 

·         Amongst the above enlisted applications, dermal toxicity is expected to witness significant progress with a CAGR of approximately 13% due to comparatively higher incidence of side effects associated with skin after administration of several compounds. 

·         North America accounted for the largest share of over 45% in revenue in 2014 owing to presence of significant number of sector players that are implementing advanced in-vitro technology. Furthermore, presence of stringent regulations pertaining to animal usage in toxicity analysis attributive towards high demand of in-vitro tests in this region. 

·         Asia Pacific is expected to witness lucrative CAGR of over 11% from 2015 to 2022 due to rapid improvement in health care infrastructure in developing economies of this region which in turn contributes to regional progress in industry. 

·         Key participants of in-vitro toxicology testing industry are Quest Diagnostics, Covance, Cyprotex, Alere, Inc, Charles River Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, Inc., Agilent Technologies, Catalent Pharma Solutions, Sigma Aldrich, and Bio-Rad. 

·         These participants are involved in collaborations with bioinformatics research firms in order to develop novel in-silico algorithms for computational estimation of toxicity of pharmaceutical and chemical products. 

·         Moreover, these market entities are also focusing on entering untapped regions in order to maintain their share in market revenue. 

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented in-vitro toxicology testing market on the basis of end use, technology, method, application, and region:
Global In-vitro Toxicology Testing Outlook, by End-use (Revenue, USD Million, 2012 – 2022)

·         Pharmaceutical industry

·         Cosmetics & household products

·         Diagnostics

·         Chemical industry

·         Food industry

Global In-vitro Toxicology Testing Technology Outlook (Revenue, USD Million, 2012 – 2022)

·         Cell culture technology

·         High throughput technology

·         Molecular imaging

·         OMICS technology

Global In-vitro Toxicology Testing Outlook, by Application (Revenue, USD Million, 2012 – 2022)

·         Systemic Toxicology

·         Dermal Toxicity

·         Endocrine Disruption

·         Occular toxicity

Global In-vitro Toxicology Testing Outlook, by Method (Revenue, USD Million, 2012 – 2022)

·         Cellular Assay

·         Biochemical Assay

·         In-Silico

·         Ex-vivo

In-vitro Toxicology Testing Regional Outlook (Market Revenue in USD Million, 2012 - 2022 )

·         North America

·         Europe

·         Asia Pacific

·         RoW

Hemodynamic Monitoring Devices Market Is Rising Prevalence Of Chronic Illness And Its Enhanced Demand For Non-Invasive Monitoring Techniques Till 2024: Grand View Research, Inc.

The global Hemodynamic Monitoring Devices Market is expected to reach USD 1.4 billion by 2024, according to a new report by Grand View Research, Inc. The increasing demand for non-invasive monitoring techniques coupled with the rising prevalence of chronic illness is expected to drive the market over the overcast period. 

The hemodynamic monitoring market is influenced by new technologies such as echocardiography, thoracic electrical bio-impedance and others that maybe used to non-invasively monitor parameters such as cardiac output, arterial pressure, blood oxygen level, and central venous pressure. 

Furthermore, the rising population of critically ill patients coupled with defective healthcare facilities with drawbacks, such as understaffing, is propelling market players to develop minimal invasive hemodynamic monitoring devices that may be used in clinical and home care settings. Along with the new product development, the market is also anticipated to witness the development of technologies that help in the early diagnosis of shock and sepsis. 

Furthermore, efforts by key industry players to understand critical illnesses at molecular levels leading to the development of efficient assessment products are expected to be witnessed over the forecast period. Hence, all these company strategies and the research conducted are eventually expected to promote market growth over the forecast period.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/hemodynamic-monitoring-devices-market

North America Hemodynamic Monitoring Devices Market share, by product, 2014-2024 (USD Million)

 

Further key findings from the study suggest:

·         The disposables segment is anticipated to be the largest segment by 2024. The rising sale of hemodynamic monitoring systems and increasing applications of these systems in home care settings, hospitals, and clinics are expected to boost the segment growth.

·         The non-invasive devices segment is expected to be the fastest growing hemodynamic monitoring market. Risks that include the development of arrhythmias due to the use of pulmonary artery catheter and the development of other methodologies that measure the cardiac output, such as echocardiographs, are the vital impact rendering drivers.

·         Asia Pacific is anticipated to be the fastest growing regions and is anticipated to contribute to about 20.0% of the global revenue by 2024. The strengthening of the distribution channels by companies and the registration of products in countries, such as China, India, Australia, and others, are expected to support the growth over the forecast period. For instance, LiDCO Group, in their 2016 prelim report emphasized on its strategy of appointing new distributors for the Australian and South East Asian region.

·         Major industry players are Edward Lifesciences, LiDCO Group Plc, Deltex Medical, Philips Medical, GE Healthcare, Noninvasive Medical Technologies, Inc., Tensys Medical, Inc., Cardio-Dynamics International, and Drager Medical, Inc. As mentioned above, the new product development is expected to drive the market over the forecast period.

·         For instance, in March 2016, the LiDCO Group received the U.S. FDA approval for the LiDCO unity and launched the product in the European region. Along the same time, LiDCO also succeeded in registering itself in China to explore untapped territories and increase their global presence.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the Hemodynamic Monitoring Devices Market on the basis of product, type, end-use and regions. 

Global Hemodynamic Monitoring Devices Product Outlook (Revenue, USD Million, 2014 – 2024)

·         Monitoring systems

·         Pulmonary artery catheters

·         Cardiac output monitors

·         Others

·         Disposables

·         Probes

·         Airflow Sensors

·         Circuits

·         Others

·         Services

Global Hemodynamic Monitoring Devices Type Outlook (Revenue, USD Million, 2014 – 2024)

·         Invasive Hemodynamic Monitoring System

·         Minimally Invasive Hemodynamic Monitoring System

·         Non-invasive Hemodynamic Monitoring System

Global Hemodynamic Monitoring Devices End-use Outlook (Revenue, USD Million, 2014 – 2024)

·         Hospitals

·         Catheterization Laboratories

·         Others

Hemodynamic Monitoring Devices Market Regional Outlook (Revenue, USD Million, 2014 – 2024)

·         North America

·         U.S.

·         Canada

·         Europe

·         UK

·         Germany

·         Asia Pacific

·         Japan

·         China

·         Latin America

·         Brazil

·         Mexico

·         MEA

·         South Africa

·         Saudi Arabia